Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 13/20 | 0.50 |
| ▸ | PIM1 | P11309 | 9/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.42 |
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11907517 | 1.00 | PIM2 (0.50) | PIM2PIM3PIM1MAP4K4PRKCA | |
| SCHEMBL4555798 | 0.89 | PIM2 (0.48) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL11908095 | 0.89 | PIM2 (0.48) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL4554934 | 0.87 | BTK (0.42) | PIM2PIM3PIM1MAP4K4BTK | |
| SCHEMBL11907439 | 0.86 | PIM2 (0.55) | PIM2PIM3PIM1MAP4K4PRKCA | |
| SCHEMBL4555708 | 0.86 | PIM2 (0.55) | PIM2PIM3PIM1MAP4K4PRKCA | |
| SCHEMBL16004030 | 0.84 | PIM2 (0.41) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL15996772 | 0.83 | PIM2 (0.48) | PIM2PIM3PIM1PRKCAGSK3B | |
| SCHEMBL4570885 | 0.82 | PIM2 (0.51) | PIM2PIM3PIM1MAP4K4PRKCA | |
| SCHEMBL4570884 | 0.82 | PIM2 (0.51) | PIM2PIM3PIM1MAP4K4PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-8822497-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM3 3/4885PIM1 1/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | PIM2 2/4885PIM3 3/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.